Jennifer Taylor
Psychiatric/Mental Health · Juneau, WINPI 1457786667
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 147 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $712 and has fallen 52.9% since, to $335 in 2025.
Across 147 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$487
- Alkermes, Inc.$477
- Otsuka America Pharmaceutical, Inc.$236
- Takeda Pharmaceuticals U.S.A., Inc.$214
- AbbVie$160
- Corium, LLC$141
- plus $737 from 11 others
What the payments were for
- Food & beverage$2,452100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 27 | $487 |
| Alkermes, Inc. | 26 | $477 |
| Otsuka America Pharmaceutical, Inc. | 21 | $236 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $214 |
| AbbVie | 12 | $160 |
| Corium, LLC | 9 | $141 |
| Johnson & Johnson | 8 | $133 |
| Indivior Inc. | 5 | $102 |
| Supernus Pharmaceuticals, Inc. | 5 | $88 |
| Axsome Therapeutics, Inc. | 4 | $81 |
| Teva Pharmaceuticals USA, Inc. | 4 | $77 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $76 |
| E.r. Squibb & Sons, L.L.C. | 4 | $75 |
| Vanda Pharmaceuticals Inc. | 3 | $57 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| USWM, LLC | 1 | $15 |
How this compares
$2,452 in reported general payments places this provider in the 85th percentile of 384 psychiatric/mental health providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 32 | $46,728 |
| VraylarCariprazine Hcl | 18 | $27,972 |
| VivitrolNaltrexone Microspheres | 11 | $17,292 |
| TrintellixVortioxetine Hydrobromide | 28 | $14,701 |
| Aripiprazole | 81 | $2,436 |
| Bupropion XlBupropion Hcl | 86 | $1,605 |
| Duloxetine Hcl | 68 | $1,253 |
| Buspirone Hcl | 30 | $930 |
| Divalproex Sodium ErDivalproex Sodium | 15 | $889 |
| Risperidone | 35 | $828 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 47 | $813 |
| Gabapentin | 52 | $806 |
| Quetiapine Fumarate | 72 | $785 |
| Trazodone Hcl | 65 | $698 |
| Prazosin Hcl | 23 | $687 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $236 | $46,72832 claims |
| AbbVieVraylar | $160 | $27,97218 claims |
| Alkermes, Inc.Vivitrol | $477 | $17,29211 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $214 | $14,70128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 384 psychiatric/mental health providers in Wisconsin.
Other psychiatric/mental health in Juneau
- Amanda Reda-GoglioJuneau$7K
- Michelle ZapinskiJuneau$5K
- Carolyn DavidsonMilwaukee$46K
- Sherry AleksichMilwaukee$33K
- Bobbi DurstPewaukee$23K
- Ngozi ObioraMilwaukee$19K
- Glenda McConnellGreen Bay$14K
- Debra BenishekGreen Bay$12K
- Shalonda MylesBrown Deer$12K
- Victoria McGinleyMilwaukee$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.